Enhertu 100 mg powder for concentrate for solution for infusion clinical trials

A multicentre, prospective, open-label study with [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2-antibody drug conjugates in patients with metastatic breast cancer (HER2-Ex PET)

This study looks at a new special scan for breast cancer to see how HER2 protein levels affect treatment. It uses a new drug called Enhertu to treat metastatic breast cancer and aims to find out if the scan can predict how well the treatment will work.